# Everolimus With or Without Bevacizumab in Treating Patients With Advanced Kidney Cancer That Progressed After First-Line Therapy

> **NCT01198158** · PHASE3 · TERMINATED · sponsor: **National Cancer Institute (NCI)** · enrollment: 77 (actual)

## Conditions studied

- Clear Cell Renal Cell Carcinoma
- Recurrent Renal Cell Carcinoma
- Stage III Renal Cell Cancer AJCC v7
- Stage IV Renal Cell Cancer AJCC v7

## Interventions

- **BIOLOGICAL:** Bevacizumab
- **DRUG:** Everolimus
- **OTHER:** Laboratory Biomarker Analysis
- **OTHER:** Pharmacological Study

## Key facts

- **NCT ID:** NCT01198158
- **Lead sponsor:** National Cancer Institute (NCI)
- **Sponsor class:** NIH
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2010-09-15
- **Primary completion:** 2017-12-15
- **Final completion:** 2017-12-16
- **Target enrollment:** 77 (ACTUAL)
- **Last updated:** 2019-03-06


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01198158

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01198158, "Everolimus With or Without Bevacizumab in Treating Patients With Advanced Kidney Cancer That Progressed After First-Line Therapy". Retrieved via AI Analytics 2026-05-31 from https://api.ai-analytics.org/clinical/NCT01198158. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*